The Ureteral Stents market is expected to grow at a CAGR of 5.6% to reach US$ 828.4 Mn in 2030.
The global ureteral stents market was valued at USD 389.8 Million in 2020 and is projected to grow at a CAGR of 6.8% during the forecast period. Factors driving the growth of the ureteral stents market include growing burden of urological conditions, the acceptance of technologically innovative stents for safe and effective urological processes and increasing number of kidney transplants.
The ureter is a vital thin tube structure allowing the urine that is produced by the kidney, to drain into the bladder. If this tube becomes blocked, it can result in pain, life threatening infection and damage to the kidney. A ureteric stent is a plastic tube used to keep the kidney draining and prevent these problems. There are curls on each end to stop the stent from moving. Stents are temporary and in some circumstances, a small length of string is attached to the lower part of the stent to facilitate removal.
Regionally, North America accounted for the largest market share of the global ureteral stents market attributable to sedentary lifestyle causing urological and kidney-related complaints. Leading players of the global ureteral stents market include Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, BD, Medline Industries, Coloplast Ltd., Allium Medical Solutions Ltd., Teleflex Incorporated, Merit Medical Systems, Olympus Corporation among others.
Ureteral Stents Market Scope
Metrics | Details |
Base Year | 2023 |
Historic Data | 2018-2022 |
Forecast Period | 2024-2030 |
Study Period | 2018-2030 |
Forecast Unit | Value (USD) |
Revenue forecast in 2030 | US$ 828.4 Million |
Growth Rate | CAGR of 5.6% during 2020-2030 |
Segment Covered | Material, Application, Regions |
Regions Covered | North America, Europe, Asia Pacific, South America, Middle East and Africa |
Key Players Profiled | Boston Scientific Corporation, Cook Medical, B. Braun Melsungen AG, BD, Medline Industries, Coloplast Ltd., Allium Medical Solutions Ltd., Teleflex Incorporated, Merit Medical Systems, Olympus Corporation among others. |
Key segments of the global ureteral stents market
Material Overview, (USD Million)
- Metallic Ureteral Stents
- Polymer Ureteral Stents
Application Overview, (USD Million)
- Kidney Stones
- Kidney Transplantation
- Tumours
- Others
Regional Overview, (USD Million)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- GCC
- South Africa
Reasons for the study
- Increasing burden of urological disorders
- Awareness campaigns initiated by smart government and other organization
What does the report include?
- The study on the global ureteral stents market includes qualitative factors such as drivers, restraints and opportunities
- The study covers qualitative and quantitative analysis of the market segmented on the basis of material and application. Moreover, the study provides similar information for the key geographies.
- Actual market sizes and forecasts have been provided for all the above-mentioned segments
- The study includes the profiles of key players in the market with a significant global and/or regional presence
Who should buy this report?
- The report on the global ureteral stents market is suitable for all the players across the value chain including product manufacturing companies, suppliers/distributors, R&D labs, CROs, healthcare organizations, medical reimbursement and insurance providers
- Venture capitalists and investors looking for more information on the future outlook of the global ureteral stents market
Consultants, analysts, researchers, and academicians looking for insights shaping the global ureteral stents market
Frequently Asked Questions (FAQ) :
The current growth in usage of ureteral stents in the managing of a diversity of urinary tract disease procedures mandates expertise with these devices, their consequences, and their latent complications, which at times can be distressing. Radiology plays a significant role in the monotonous observing of stents and in the assessment of these consequences and impediments. It may also bid solutions for their improvement. Stents must be checked while in place, quickly removed when no longer required, and changed occasionally if persistently indwelling. Risk factors for impediments should be curtailed with high fluid consumption, timely assessment of clinical grievances, and aggressive treatment of recognized infection. Certain patients may perhaps not be best aided by indwelling stent placement, and urinary diversion by means of other mechanisms may be directed. The instilling physician is accountable for notifying the patient of the necessities, penalties, and problems accompanying stent placement. Failure to do so has apparent management and probable medico legal repercussions.
On the basis of application, the market is segmented into kidney stones, kidney transplantation, tumors, others. The kidney stones segment dominated the market in 2020. Kidney stones are surprisingly common. In fact, more than 5% of the U.S. population has had one, and the lifetime risk of having a kidney stone is about 1 in 7. The most common age group is 20 to 40 years old, but they can occur in children and senior citizens alike. Men are three times more likely than women to have kidney stones. The ureter has some normal swelling after a kidney stone procedure. The stent keeps this swelling from blocking the ureter and also prevents severe pain after a procedure. If the ureter is swollen shut, there is a severe stone-like pain for 3 to 7 days. With a stent, urine flows freely without this pain. It helps widen the ureter so small stone fragments pass more easily.
North America accounted for the largest share of the global ureteral stents market in 2020. Moreover, Asia is likely to show lucrative growth during the forecast period. Bladder cancer is the tenth commonest cancer in Australia, accounting for approximately 2% of all new cancers. In keeping with most other countries, the incidence of bladder cancer in Australia is more than three times higher in men than in women. Unfortunately, bladder cancer is the only cancer in Australia in which survival is worsening; five-year survival has fallen from 68% to 58% in the past 30 years. Of additional concern is the significantly lower five-year survival for women, which is 50%, as compared with 60% in men. In such circumstances, the ureteral stents market is set to prosper in the region.